Project overview
National Biofilms Innovation Centre (NBIC), UK. Proof of Concept (POC) Round 1 (Research Grant). £147,727 (£65,994.50 from NBIC, £81,732.50 from Destiny Pharma).
Antibiotic-resistant bacteria, particularly within biofilms and fungi pose a significant healthcare threat including respiratory conditions, (e.g. Cystic Fibrosis) and chronic wounds such as diabetic foot ulcers (DFU). The purpose of this NBIC study is to examine the effectiveness of a novel antimicrobial-drug series in two mechanistically-distinct and clinically relevant model systems.
Antibiotic-resistant bacteria, particularly within biofilms and fungi pose a significant healthcare threat including respiratory conditions, (e.g. Cystic Fibrosis) and chronic wounds such as diabetic foot ulcers (DFU). The purpose of this NBIC study is to examine the effectiveness of a novel antimicrobial-drug series in two mechanistically-distinct and clinically relevant model systems.
Staff
Lead researcher
Other researchers
Collaborating research institutes, centres and groups
Microbiology
We work on topics like patient treatment regimens, catheter design and management, and surgical instrument decontamination.
Biofilms
Biofilms are a collective of one or more types of microorganisms that can grow on different surfaces. Their impact is central to some of the most urgent global challenges, including food and water security, antimicrobial resistance (AMR), infections disease and contamination and more.